MarketPulse

Phase 2

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Assembly Biosciences Advances Pipeline With $226.6M Cash Runway Into 2028

Assembly Biosciences reports Q1 2026 results with $226.6M cash runway into 2028, completing Phase 1b herpes studies and advancing hepatitis delta candidate toward Phase 2.
GILDASMBclinical developmentGilead Sciences
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Rein Therapeutics Raises $50M via IPO to Fund Pulmonary Fibrosis Trial

Rein Therapeutics prices $50M stock offering at $1.00 per share to fund LTI-03 Phase 2 trial for idiopathic pulmonary fibrosis, with cash runway extended through 2028.
RNTXclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Spyre Therapeutics, Inc.

Spyre's SPY001 Shows Promise in Ulcerative Colitis With Strong SKYLINE Trial Data

Spyre Therapeutics reports positive Phase 2 results for SPY001 in ulcerative colitis, meeting primary endpoints with significant histopathology improvements and favorable safety.
SYREulcerative colitisclinical remission
The Motley FoolThe Motley Fool··Micah Zimmerman

AI Investment Shifts to Infrastructure Phase: Two Overlooked Winners Emerge

AI investment enters Phase 2, shifting from chip hype to infrastructure validation. Keysight and Calix positioned to benefit from data center validation and rural broadband deployment.
NVDAGOOGGOOGLKEYSCALXdata centerinfrastructure
GlobeNewswire Inc.GlobeNewswire Inc.··Askbio Inc.

Bayer-Owned AskBio Completes Phase 2 Trial Enrollment for Heart Failure Gene Therapy

AskBio completes enrollment of 173 patients in Phase 2 trial for AB-1002 gene therapy targeting heart failure. Results expected H1 2027.
BAYRYclinical trialheart failure
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics to Unveil 52-Week Phase 2 Data for APG777 Atopic Dermatitis Treatment

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.
APGEbiologicsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials